Phase III development of bapineuzumab (Janssen Alzheimer Immunotherapy) in Alzheimer's disease discontinued

Janssen Alzheimer Immunotherapy has announced that its Phase III clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease is being discontinued. This is based on the co-primary clinical endpoints not being met in the Janssen AI-led Studies 301 and 302. Four placebo-controlled Phase III studies comprised the bapineuzumab clinical development program. Janssen AI led the two completed 18-month, Phase III studies of patients who are ApoE4 carriers (Study 302) and ApoE4 non-carriers (Study 301). In addition, Pfizer led two primarily ex-North America 18-month, Phase III studies of patients with mild-to-moderate Alzheimer's disease who are ApoE4 non-carriers (Study 3000) and carriers (Study 3001).